Collectively, these results suggest that both acute and chronic treatment with a SERT inhibitor might reduce dyskinesia severity, while de novo treatment with a SERT inhibitor might attenuate the priming leading to the expression of dyskinesia. The gene discussed is SLC6A4; the disease is Dyskinesia.